Contribution of Early Clinical Benefit End Points to Decreased Lung Cancer Mortality Rates

This Viewpoint discusses how the approval and widespread adoption of novel therapeutics into clinical practice may have contributed to the decline in non–small cell lung cancer mortality rates, outpacing the increased incidence.

Source:

JAMA Oncology